Accelerating Immune Reconstitution After Hematopoietic Stem Cell Transplantation

Overview

Journal Clin Transl Immunology

Specialty Allergy & Immunology

Date 2014 Dec 16

PMID 25505959

Citations 6

Authors

Ifigeneia Tzannou

Ann M Leen

Affiliations

Soon will be listed here.

Abstract

Viral infections remain a significant cause of morbidity and mortality after hematopoietic stem cell transplantation. Pharmacologic agents are effective against some pathogens, but they are costly and can be associated with significant toxicities. Thus, many groups have investigated adoptive T-cell transfer as a means of hastening immune reconstitution and preventing and treating viral infections. This review discusses the immunotherapeutic strategies that have been explored.

Citing Articles

Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients.

Forlanini F, Dara J, Dvorak C, Cowan M, Puck J, Dorsey M Transpl Infect Dis. 2020; 23(2):e13504.

PMID: 33169931 PMC: 8287897. DOI: 10.1111/tid.13504.

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez C, Ramos C J Clin Oncol. 2017; 35(31):3547-3557.

PMID: 28783452 PMC: 5662844. DOI: 10.1200/JCO.2017.73.0655.

Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy.

Li Pira G, Di Cecca S, Biagini S, Girolami E, Cicchetti E, Bertaina V Front Immunol. 2017; 8:332.

PMID: 28386262 PMC: 5362590. DOI: 10.3389/fimmu.2017.00332.

[Comparison of immune reconstitution at early stage after unmanipulated haploidentical stem cell transplantation between high- and standard- risk Philadelphia chromosome- negative acute lymphoblastic leukemia patients in CR1].

Bian Z, Chang Y, Xu L, Wang Y, Zhang X, Liu K Zhonghua Xue Ye Xue Za Zhi. 2016; 37(8):650-5.

PMID: 27587244 PMC: 7348535. DOI: 10.3760/cma.j.issn.0253-2727.2016.08.004.

Mechanisms of blood homeostasis: lineage tracking and a neutral model of cell populations in rhesus macaques.

Goyal S, Kim S, Chen I, Chou T BMC Biol. 2015; 13:85.

PMID: 26486451 PMC: 4615871. DOI: 10.1186/s12915-015-0191-8.

References

Hamstra D, Page M, Maybaum J, Rehemtulla A . Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs. Cancer Res. 2000; 60(3):657-65. View

Guinan E, Boussiotis V, Neuberg D, Brennan L, Hirano N, Nadler L . Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999; 340(22):1704-14. DOI: 10.1056/NEJM199906033402202. View

Peggs K, Verfuerth S, Pizzey A, Chow S, Thomson K, Mackinnon S . Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis. 2009; 49(12):1851-60. DOI: 10.1086/648422. View

Ge X, Brown J, Sykes M, Boussiotis V . CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol Blood Marrow Transplant. 2008; 14(5):518-30. PMC: 2423190. DOI: 10.1016/j.bbmt.2008.02.010. View

Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E . Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001; 97(1):63-72. DOI: 10.1182/blood.v97.1.63. View

Gottschalk S, Ng C, Perez M, Smith C, Sample C, Brenner M . An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001; 97(4):835-43. DOI: 10.1182/blood.v97.4.835. View

Munshi N, Govindarajan R, Drake R, Ding L, Iyer R, Saylors R . Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood. 1997; 89(4):1334-40. View

Hanley P, Cruz C, Savoldo B, Leen A, Stanojevic M, Khalil M . Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009; 114(9):1958-67. PMC: 2738578. DOI: 10.1182/blood-2009-03-213256. View

Heslop H, Ng C, Li C, Smith C, Loftin S, Krance R . Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996; 2(5):551-5. DOI: 10.1038/nm0596-551. View

10.

Lindemans C, Leen A, Boelens J . How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood. 2010; 116(25):5476-85. PMC: 3031399. DOI: 10.1182/blood-2010-04-259291. View

11.

Heslop H . How I treat EBV lymphoproliferation. Blood. 2009; 114(19):4002-8. PMC: 2774540. DOI: 10.1182/blood-2009-07-143545. View

12.

Neudorfer J, Schmidt B, Huster K, Anderl F, Schiemann M, Holzapfel G . Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods. 2007; 320(1-2):119-31. DOI: 10.1016/j.jim.2007.01.001. View

13.

van Dijk A, Kessler F, Verdonck L, de Gast G, Otten H . Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol. 1999; 107(1):169-75. DOI: 10.1046/j.1365-2141.1999.01675.x. View

14.

Doubrovina E, Oflaz-Sozmen B, Prockop S, Kernan N, Abramson S, Teruya-Feldstein J . Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2011; 119(11):2644-56. PMC: 3311278. DOI: 10.1182/blood-2011-08-371971. View

15.

Blyth E, Clancy L, Simms R, Ma C, Burgess J, Deo S . Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013; 121(18):3745-58. DOI: 10.1182/blood-2012-08-448977. View

16.

Huber B, Richards C, KRENITSKY T . Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci U S A. 1991; 88(18):8039-43. PMC: 52441. DOI: 10.1073/pnas.88.18.8039. View

17.

Gustafsson A, Levitsky V, Zou J, Frisan T, Dalianis T, Ljungman P . Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000; 95(3):807-14. View

18.

Bell M, Burrows J, Brennan R, Miles J, Tellam J, McCluskey J . The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length. Mol Immunol. 2009; 46(8-9):1911-7. DOI: 10.1016/j.molimm.2008.12.003. View

19.

Hartwig U, Nonn M, Khan S, Meyer R, Huber C, Herr W . Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant. 2005; 37(3):297-305. DOI: 10.1038/sj.bmt.1705238. View

20.

Nonn M, Herr W, Khan S, Todorova M, Link I, Thies J . Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering. Transplantation. 2008; 86(10):1427-35. DOI: 10.1097/TP.0b013e31818810d6. View